Colorectal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Colon Cancer (151)

Rectal Cancer (65)

Colorectal Adenocarcinoma (8)

Colon Cancer (151)

Rectal Cancer (65)

Colorectal Adenocarcinoma (8)

›

HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	HER-2 amplification + RAS wild-type + BRAF wild-type	Colon Cancer	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week (New A2) trastuzumab + tucatinib Sensitive : A2 NCCN - 1wk	trastuzumab + tucatinib Sensitive: A2 - Guideline NCCN - 1 week trastuzumab + tucatinib Sensitive : A2 NCCN - 1 week - (New A2)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks (New A1) trastuzumab + tucatinib Sensitive : A1 FDA - 2wk	trastuzumab + tucatinib Sensitive: A1 - Approval FDA - 2 weeks trastuzumab + tucatinib Sensitive : A1 FDA - 2 weeks - (New A1)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) panitumumab Sensitive : C3 ASCO-GI 2023 - 2wk	panitumumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks panitumumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks (New C3) erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 2wk	erlotinib + vemurafenib Sensitive: C3 – Early Trials Clin Cancer Res - 2 weeks erlotinib + vemurafenib Sensitive : C3 Clin Cancer Res - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive	Colorectal Cancer	BRAF wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2wk	trastuzumab + pertuzumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks trastuzumab + pertuzumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	regorafenib Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) regorafenib Resistant : C3 ASCO-GI 2023 - 2wk	regorafenib Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks regorafenib Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MUC16 elevation	Colorectal Cancer	MUC16 elevation	Colorectal Cancer	trifluridine/tipiracil Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) trifluridine / tipiracil Resistant : C3 ASCO-GI 2023 - 2wk	trifluridine/tipiracil Resistant: C3 – Early Trials ASCO-GI 2023 - 2 weeks trifluridine / tipiracil Resistant : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab + ipilimumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab + ipilimumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	CEACAM5 underexpression + MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
THBS2-L	Colorectal Cancer	THBS2-L	Colorectal Cancer	ramucirumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) ramucirumab Sensitive : C3 ASCO-GI 2023 - 2wk	ramucirumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks ramucirumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) nivolumab Sensitive : C3 ASCO-GI 2023 - 2wk	nivolumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks nivolumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	MSI-H/dMMR + CD74 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPA1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DQB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-B overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DRB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
EREG overexpression + AREG overexpression	Colorectal Cancer	EREG overexpression + AREG overexpression	Colorectal Cancer	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR + RAS mutation	Colorectal Cancer	MSI-H/dMMR + RAS mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2wk	Immunotherapy Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks Immunotherapy Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2wk	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks AGEN2034 + AGEN1181 Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) nivolumab Sensitive : D ASCO-GI 2023 - 2wk	nivolumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks nivolumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	MSI-H/dMMR + HLA-DPB1 overexpression	Colorectal Cancer	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) pembrolizumab Sensitive : D ASCO-GI 2023 - 2wk	pembrolizumab Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks pembrolizumab Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation	Colorectal Cancer	PIK3CA mutation + KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
ROS1 amplification	Colon Cancer	ROS1 amplification	Colon Cancer	metformin + efavirenz + fluoxetine Sensitive: D – Preclinical Cancer Biol Ther - 4 weeks (New D) metformin + efavirenz + fluoxetine Sensitive : D Cancer Biol Ther - 4wk	metformin + efavirenz + fluoxetine Sensitive: D – Preclinical Cancer Biol Ther - 4 weeks metformin + efavirenz + fluoxetine Sensitive : D Cancer Biol Ther - 4 weeks - (New D)
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval cetuximab + encorafenib + binimetinib Sensitive : A1
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1	cetuximab + encorafenib Sensitive: A1 - Approval cetuximab + encorafenib Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1	FOLFIRI Sensitive: A1 - Approval FOLFIRI Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1	5-fluorouracil + irinotecan Sensitive: A1 - Approval 5-fluorouracil + irinotecan Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1	bevacizumab-bvzr Resistant: A1 - Approval bevacizumab-bvzr Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1	trifluridine/tipiracil Sensitive: A1 - Approval trifluridine / tipiracil Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ziv-aflibercept IV Sensitive: A1 - Approval ziv-aflibercept IV Sensitive : A1	ziv-aflibercept IV Sensitive: A1 - Approval ziv-aflibercept IV Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1	capecitabine Sensitive: A1 - Approval capecitabine Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
KRAS Q61	Colorectal Cancer	KRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
KRAS A146	Colorectal Cancer	KRAS A146	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
No biomarker	Colon Cancer	No biomarker	Colon Cancer	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1	irinotecan Sensitive: A1 - Approval irinotecan Sensitive : A1
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
KRAS K117	Colorectal Cancer	KRAS K117	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS A59	Colorectal Cancer	KRAS A59	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
KRAS G12S	Colorectal Cancer	KRAS G12S	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1
NRAS Q61	Colorectal Cancer	NRAS Q61	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS G13	Colorectal Cancer	NRAS G13	Colorectal Cancer	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1	cetuximab Resistant: A1 - Approval cetuximab Resistant : A1

Colorectal Cancer

Associations(1218)

Associations
(1218)